Orgenesis Inc. (NASDAQ:ORGS – Get Free Report)’s stock price traded up 490% on Monday . The company traded as high as $0.59 and last traded at $0.59. 100 shares changed hands during mid-day trading, a decline of 90% from the average session volume of 959 shares. The stock had previously closed at $0.10.
Orgenesis Trading Up 490.0%
The company has a market capitalization of $3.05 million, a price-to-earnings ratio of -0.05 and a beta of 3.22. The firm’s 50 day simple moving average is $0.31 and its 200-day simple moving average is $0.39.
About Orgenesis
Orgenesis, Inc is a cell and gene therapy company that develops and commercializes point-of-care manufacturing platforms for autologous and allogeneic therapies. The company offers an end-to-end solution that spans from R&D through clinical and commercial production, targeting applications in oncology, neurology, and various rare diseases. Orgenesis’ technology platforms are designed to streamline the complex processes involved in cell isolation, genetic modification, expansion and cryopreservation.
The company’s flagship offering is its automated Prodigy® platform, which integrates cell processing workflows into a closed, single-use system.
Further Reading
- Five stocks we like better than Orgenesis
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
